The mouse grid-shock analgesia test: pharmacological characterization of latency to vocalization threshold as an index of antinociception

MD Swedberg

Pharmaceuticals Division, Novo Nordisk, Malov, Denmark.

Latency to vocalization and jump/flinch behaviors were scored as the nociceptive endpoints in mice in a grid-shock apparatus that delivered increasing shock levels through a grid floor. Morphine produced a dose- dependent increase in latency to vocalization and was equieffective at a 70- or 80-dB vocalization level. The jump/flinch behavior was not dose dependently modified by morphine. The mouse grid-shock procedure was pharmacologically characterized by using the 70-dB level endpoint. The antinociceptive potencies of the mu opioid receptor agonist analgesics, morphine, methadone, fentanyl, oxycodone, meperidine, etorphine and codeine, correlated well (R = .989) with their clinical doses. The mixed opioid agonist-antagonist, pentazocine, and the partial mu receptor opioid agonist, buprenorphine, were partially effective. The alpha-2 adrenergic agonists clonidine and flupirtine and the serotonergic 5-HT1B agonists 1-(m-trifluoromethyl)piperazine and anpirtoline, were all effective antinociceptives with potencies 20 times less to one-half that of morphine. The gamma-aminobutyric acid agonist 4,5,6,7-tetrahydroisoxazolo[5,4- c]pyridin-3(2H)-one was partially effective, whereas the gamma-aminobutyric acid uptake inhibitors SKF 100300A [N-(4,4-diphenyl-3-butenyl)-guvacine] and tiagabine were highly effective and 6 and 2 times less potent than morphine, respectively. The muscarinic agonists, oxotremorine and arecoline, and the cholinesterase inhibitor, physostigmine, were also antinociceptive, ranging from 7 times less to 100 times more potent than morphine. The nonsteroidal anti-inflammatory analgesic, aspirin, was inactive. The present studies show that the latency to a defined level of vocalization as the nociceptive endpoint provides a reliable, highly reproducible and high through-put test for antinociception in nonrestrained mice.

Volume 269, Issue 3, pp. 1021-1028, 06/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. Le Bars, M. Gozariu, and S. W. Cadden Animal Models of Nociception Pharmacol. Rev., December 1, 2001; 53(4): 597 - 652. [Abstract] [Full Text] [PDF]

				M. J. Sheardown, H. E. Shannon, M. D. B. Swedberg, P. D. Suzdak, F. P. Bymaster, P. H. Olesen, C. H. Mitch, J. S. Ward, and P. Sauerberg M1 Receptor Agonist Activity Is Not a Requirement for Muscarinic Antinociception J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 868 - 868. [Abstract] [Full Text]

				M. D. B. Swedberg, M. J. Sheardown, P. Sauerberg, P. H. Olesen, P. D. Suzdak, K. T. Hansen, F. P. Bymaster, J. S. Ward, C. H. Mitch, D. O. Calligaro, et al. Butylthio[2.2.2] (NNC 11-1053/LY297802): An Orally Active Muscarinic Agonist Analgesic J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 876 - 883. [Abstract] [Full Text]